Trial Profile
Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2023
Price :
$35
*
At a glance
- Drugs LN 145 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Ipilimumab; Nivolumab
- Indications Carcinoma; Cervical cancer; Chondrosarcoma; Giant cell tumours; Malignant fibrous histiocytoma; Osteosarcoma; Ovarian cancer; Sarcoma; Soft tissue sarcoma; Thyroid cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms Iovance Alliance
- 04 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 23 May 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 24 Jun 2021 Planned number of patients changed from 80 to 95.